Research Programs

IPCT Seed Funding Award Recipients

Jaffer Ajani, M.D.
Esophageal Preservation in Select Esophageal Cancer Patients through Biomarker and Imaging Signatures

Peter Anderson, M.D., Ph.D., Michael Rytting, M.D.
Individual Drug Discovery: A Proactive Approach

Howard Colman, M.D., Ph.D., Kenneth Aldape, M.D.
A Multigene Predictor for Individualization of Patient Treatment in Newly Diagnosed Glioblastoma Multiforme (GBM)

Laurence Cooper, M.D., Ph.D., Richard Champlin, M.D.
Applied Cell Therapy (ACT)

Gilbert Cote, Ph.D., Steven Sherman, M.D.
RET and BRAF Mutations in Thyroid Cancer

Randa El-Zein, M.D., Ph.D.
MGMT Enzyme Activity as a Modulator of Glioma Treatment Outcome

Mitchell Frederick, Ph.D., Jeffrey Myers, M.D., Ph.D.
Profiling Biomarkers in Head and Neck Cancer Patients Treated Preoperatively with Cetuximab and/or IMC-A12

Jian Gu, Ph.D.
Predictors of Chemoradiotherapy Outcomes in Esophageal Cancer: An Integrative Approach

Bryan Hennessy, M.D., Karen Lu, M.D.
Phase II Study to Determine the Association Between the Presence of PI3K Pathway Mutations and the Pharmacodynamic Effects and Antitumor Efficacy of the PI3K Inhibitor SF1126 in Patients with Progressive or Recurrent Endometrial Cancer

John Heymach, M.D., Ph.D., Herbert Fritsche, Ph.D., Hai Tran, Pharm.D.
Assessment and Validation of Cytokine/ Angiogenic Factor (CAF) Profiling in Patients with Non-Small Cell Lung Cancer (NSCLC)

Christopher Holsinger, M.D.
Gene-Expression Profiles of Survival and Response to Neoadjuvant Chemotherapy for Patients with Laryngeal Cancer

Patrick Hwu, M.D.
Targeting C-KIT in Resectable Melanomas Harboring c-kit Genetic Aberrations: Correlating Biological Response with Clinical Outcomes

Faye Johnson, M.D., Ph.D.
Molecular Analysis of the Epidermal Growth Factor Receptor and K-Ras in a Large Cohort of Advanced Non-Small Cell Lung Cancer Patients

Eric Jonasch, M.D.
Determinants of Response and Resistance to Targeted Therapy in Renal Cell Carcinoma

Aarif Khakoo, M.D.
Identification of Biomarkers of Cardiotoxicity of Sunitinib

Scott Kopetz, M.D.
Nested Enrichment Trial Design in Refractory Metastatic Colorectal Cancer

Daniel Lenihan, M.D.
PREDICT - A multicenter study in Patients undergoing anthRacycline-based chemotherapy to assess the Effectiveness of using biomarkers to Detect and Identify Cardiotoxicity and describe Treatment

Dina Lev, M.D.
On the Road to Tailoring Soft Tissue Sarcoma Therapy: Identifying Chemoradiation-Response Predictive Gene Signatures

Anthony Lucci, M.D.
Improved Personalized Therapy through the Eradication of Micrometastases

Robert Orlowski, M.D., Ph.D.
Personalizing Multiple Myeloma Therapy by Use of Rational Combination Drug Regimens that Recruit Either Type I or II Programmed Cell Death

Anil Sood, M.D., Robert Coleman, M.D.
Clinical Development of Therapeutic siRNA in Ovarian Cancer

W. Fraser Symmans, M.D., Lajos Pusztai, M.D., D.Phil., Ana Gonzalez-Angulo, M.D.
Molecular Triaging of Newly Diagnosed Stage II-III Breast Cancer for Neoadjuvant Therapy

Jonathan Trent, M.D., Ph.D.
Personalized Targeted Cancer Therapy of GIST

Apostalia Tsimberidou, M.D., Ph.D., Razelle Kurzrock, M.D., J. Jack Lee, Ph.D.
Genetic Characterization of Patients Treated with Bevacizumab in Phase I Clinical Trials

Jennifer Wheler, M.D., Razelle Kurzrock, M.D., J. Jack Lee, Ph.D.
An Umbrella Protocol for Histology-Independent, Phase I Modular Study: a feasibility study based on EGFR Mutation Status using Erlotinib Alone or in Combination with Cetuximab, Bortezomib, or Dasatinib to Overcome Resistance (2007-0638)

Xifeng Wu, M.D., Ph.D.
Genome-wide Association Study on Bladder Cancer Recurrence, Survival, and Treatment Response

Anas Younes, M.D., Timothy McDonnell, M.D., Ph.D.
Biomarkers for Personalized Cancer Therapy of Lymphoma